Baseline characteristics of study populations
| Stage I: Boston (MGH) Cohort | |||
|---|---|---|---|
| Patients with pulmonary injury(n = 839) | Patients withextrapulmonary injury(n = 878) | p-value | |
| Age | 62.37±18.0 | 61.40±16.5 | 0.2276 |
| Male | 540 (64.4%) | 510 (58.1%) | 0.0086 |
| APACHE III score | 49.70±18.6 | 48.55±19.6 | 0.2199 |
| Predisposing condition | |||
| Trauma | 0 | 63 (7.2%) | <0.001 |
| Multiple transfusion | 0 | 185 (21.1%) | <0.001 |
| Sepsis | 710 (84.6%) | 665 (75.74%) | <0.001 |
| Bacteremia | 101 (12.0%) | 202 (23.0%) | <0.001 |
| Pneumonia | 775 (92.4%) | 0 | <0.001 |
| Aspiration | 28 (3.3%) | 0 | <0.001 |
| Pulmonary contusion | 47 (5.6%) | 0 | <0.001 |
| Comorbities | |||
| Diabetes | 196 (23.4%) | 230(26.2%) | 0.1796 |
| Liver cirrhosis | 41 (4.9%) | 42 (4.8%) | 1.0000 |
| History of alcohol abuse | 114 (13.6%) | 85 (9.7%) | 0.0127 |
| Developed ARDS | 290 (34.6 %) | 127 (14.5%) | <0.001 |
| Stage II | |||
| Population I (Harborview Trauma Cohort) | |||
| ALI (n=597) | No ALI (n=168) | p-value | |
| Age | 44.6±20.1 | 34.1±19.0 | < 0.001 |
| Male | 439 (73.5%) | 130 (77.4%) | 0.40 |
| Blunt trauma | 538 (90.1%) | 145 (86.3%) | 0.009 |
| ISS | 26.8±10.3 | 22.5±9.6 | < 0.001 |
| APACHE II score | 24.8±7.5 | 16.6±7.7 | < 0.001 |
| Population II (MGH/ARDS net, pneumonia/pulmonary sepsis Cohort) | |||
| ARDS (n = 392) | No ARDS (n = 446) | p-value | |
| Age | 52.32±16.14 | 64.21± 16.84 | <0.001 |
| Male | 199 (50.8%) | 161 (36.0%) | <0.001 |
| Predisposing condition | |||
| Sepsis | 212 (54.1%) | 396 (88.85) | 0.068 |
| Pneumonia | 392 (100%) | 446 (100%) | 0.965 |
| Stage III: Penn Trauma Cohort | |||
| ALI (n=74) | No ALI (n=150) | p-value | |
| Age | 41.4±20.5 | 43.9 ±20.0 | 0.27 |
| Male | 52 (69.3%) | 106 (70.2%) | 0.89 |
| Blunt | 71 (94.7%) | 141 (93.4%) | 0.71 |
| ISS | 26.4±7.6 | 25.4±7.3 | 0.34 |
| Modified APACHE III | /63.9±25.1 | 59.6±19.8 | 0.40 |
| Total pRBC 1st 24 hr | 2.59±4.8 | 1.0±2.3 | 0.007 |